Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2013 1
2014 1
2015 1
2016 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

4 results

Results by year

Filters applied: . Clear all
Page 1
Akt kinase-interacting protein1, a novel therapeutic target for lung cancer with EGFR-activating and gatekeeper mutations.
Yamada T, Takeuchi S, Fujita N, Nakamura A, Wang W, Li Q, Oda M, Mitsudomi T, Yatabe Y, Sekido Y, Yoshida J, Higashiyama M, Noguchi M, Uehara H, Nishioka Y, Sone S, Yano S. Yamada T, et al. Oncogene. 2013 Sep 12;32(37):4427-35. doi: 10.1038/onc.2012.446. Epub 2012 Oct 8. Oncogene. 2013. PMID: 23045273
Despite initial dramatic response, epidermal growth factor receptor (EGFR) mutant lung cancer patients always acquire resistance to EGFR-tyrosine kinase inhibitors (TKIs). ...Silencing of Aki1 induced apoptosis of EGFR mutant lung cancer cells. Treatment with Aki1 s …
Despite initial dramatic response, epidermal growth factor receptor (EGFR) mutant lung cancer patients always acquire resistance to E …
Akt Kinase-Interacting Protein 1 Signals through CREB to Drive Diffuse Malignant Mesothelioma.
Yamada T, Amann JM, Fukuda K, Takeuchi S, Fujita N, Uehara H, Iwakiri S, Itoi K, Shilo K, Yano S, Carbone DP. Yamada T, et al. Cancer Res. 2015 Oct 1;75(19):4188-97. doi: 10.1158/0008-5472.CAN-15-0858. Epub 2015 Aug 20. Cancer Res. 2015. PMID: 26294214 Free PMC article.
Because current treatment options are largely ineffective, novel therapeutic strategies based on molecular mechanisms and the disease characteristics are needed to improve the outcomes of patients with this disease. Akt kinase interacting protein 1 (Aki1; Freud-1/CC2D1A) i …
Because current treatment options are largely ineffective, novel therapeutic strategies based on molecular mechanisms and the disease charac …
Coupling an EML4-ALK-centric interactome with RNA interference identifies sensitizers to ALK inhibitors.
Zhang G, Scarborough H, Kim J, Rozhok AI, Chen YA, Zhang X, Song L, Bai Y, Fang B, Liu RZ, Koomen J, Tan AC, Degregori J, Haura EB. Zhang G, et al. Sci Signal. 2016 Oct 18;9(450):rs12. doi: 10.1126/scisignal.aaf5011. Sci Signal. 2016. PMID: 27811184 Free PMC article.
Patients with lung cancers harboring anaplastic lymphoma kinase (ALK) gene fusions benefit from treatment with ALK inhibitors, but acquired resistance inevitably arises. ...Using affinity purification coupled with mass spectrometry in an ALK fusion lung cancer cell …
Patients with lung cancers harboring anaplastic lymphoma kinase (ALK) gene fusions benefit from treatment with ALK inhibitors, but ac …
Expression of Akt kinase-interacting protein 1, a scaffold protein of the PI3K/PDK1/Akt pathway, in pancreatic cancer.
Ohtsubo K, Yamada T, Zhao L, Jin TF, Takeuchi S, Mouri H, Yamashita K, Yasumoto K, Fujita N, Kitagawa H, Ohta T, Ikeda H, Yano S. Ohtsubo K, et al. Pancreas. 2014 Oct;43(7):1093-100. doi: 10.1097/MPA.0000000000000168. Pancreas. 2014. PMID: 25036909
OBJECTIVES: Akt kinase-interacting protein 1 (Aki1) has been reported to be a scaffold protein of the PI3K (phosphoinositide 3-kinase)/PDK1 (3-phosphoinositide-dependent protein kinase)/Akt pathway and to interact with epidermal growth factor receptor signaling. Although Aki1 has …
OBJECTIVES: Akt kinase-interacting protein 1 (Aki1) has been reported to be a scaffold protein of the PI3K (phosphoinositide 3-kinase)/PDK1 …